Search results
Results from the WOW.Com Content Network
Disruptive mood dysregulation disorder (DMDD) is a mental disorder in children and adolescents characterized by a persistently irritable or angry mood and frequent temper outbursts that are disproportionate to the situation and significantly more severe than the typical reaction of same-aged peers.
Supporting this idea is the fact that this valve abnormality has also occurred in patients using other drugs that act on 5-HT 2B receptors. [ 23 ] [ 24 ] According to a study of 5,743 former users conducted by a plaintiff's expert cardiologist, damage to the heart valve continued long after stopping the medication. [ 25 ]
Tovorafenib, sold under the brand name Ojemda, is a medication used for the treatment of glioma. [1] [2] It is a kinase inhibitor.[1]The most common adverse reactions include rash, hair color changes, fatigue, viral infection, vomiting, headache, hemorrhage, pyrexia, dry skin, constipation, nausea, dermatitis acneiform, and upper respiratory tract infection. [3]
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."
Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. [3] It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. [3]
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), [9] but is also used to treat anxiety disorders [10] such as panic disorder, social anxiety disorder, and post-traumatic stress ...
As a provider who is certified in addiction medicine and only prescribes buprenorphine and naltrexone — two other FDA-approved medications for opioid use disorder — O’Connor said a lot of ...
Treatment of adults with locally advanced, unresectable (stage III) non- small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Repotrectinib